Kiniksa Pharmaceuticals International, plc KNSA Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's other commercial liabilities?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported other commercial liabilities of $32.77M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's other commercial liabilities changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's other commercial liabilities increased by 48.1% year-over-year, from $22.13M to $32.77M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's other commercial liabilities?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's other commercial liabilities has grown at a 7.6% compound annual growth rate (CAGR), from $29.2M to $42.02M.